Sage Therapeutics has been granted a patent for a compound of Formula (I) or its salt, along with pharmaceutical compositions containing it. The compound is intended for treating CNS-related disorders. GlobalData’s report on Sage Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Sage Therapeutics, Anti-inflammatory anesthetics was a key innovation area identified from patents. Sage Therapeutics's grant share as of May 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US11999765B2) discloses a compound of Formula (I-v) and its pharmaceutically acceptable salts. The compound is characterized by specific structural features, including the presence of R55c and the values of p and Ra. The patent claims cover various embodiments of the compound, specifying different configurations and substitutions within the chemical structure.
Furthermore, the patent extends to pharmaceutical compositions containing the disclosed compound or its pharmaceutically acceptable salts along with suitable excipients. These compositions are intended for use in the treatment of certain conditions or diseases, leveraging the unique properties of the compound. The patent provides a detailed framework for the synthesis, formulation, and potential applications of the compound in the field of pharmaceuticals.
To know more about GlobalData’s detailed insights on Sage Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.